TriangleNCT04798586 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the date of first dose until death due to any cause or censoring date (maximum of 65.1 weeks of treatment)
What was measured
Overall survival (OS) was the time from the first date of the study intervention to the date of death due to any cause. Participants not known to have died are censored on the date of last known alive.
Analysis population: SAS included all enrolled participants who received at least 1 dose of study intervention.
Groups in this outcome
Elranatamab
Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).
| Group | Source count |
|---|---|
| Elranatamab | 4 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Elranatamab | NA | Not reported | NA | NA | Data for OS was not planned to be summarized per SAP. Individual data was collected but not reported as it would lead to re-identification of participants. |
Complete source fields
- classes
- categories
- measurements
- comment
- Data for OS was not planned to be summarized per SAP. Individual data was collected but not reported as it would lead to re-identification of participants.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 4
- units
- Participants
- description
- Overall survival (OS) was the time from the first date of the study intervention to the date of death due to any cause. Participants not known to have died are censored on the date of last known alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).
- id
- OG000
- title
- Elranatamab
- param Type
- MEDIAN
- population Description
- SAS included all enrolled participants who received at least 1 dose of study intervention.
- reporting Status
- POSTED
- time Frame
- From the date of first dose until death due to any cause or censoring date (maximum of 65.1 weeks of treatment)
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice